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EXTENT OF SKELETAL INVOLVEMENT DID NOT PREDICT FOR OUTCOME
AFTER AUTOLOGOUS STEM CELL TRANSPLANT FOR PATIENTS WITH
MULTIPLE MYELOMA
Seba, A., Farhat, M., Tuncer, H., Nathan, S., Gregory, S.A., Fung, H.C.
Rush University Medical Center, Chicago, IL
Background: Autologous stem cell transplant lengthens survival
in patients with multiple myeloma, but has mortality from infections
and high costs. Determination of prognostic factors predicting pro-
longed survival prior to transplant may help determine which pa-
tients may be better candidates for autologous SCT. Here, we
hypothesized that extensive skeletal involvement prior to transplant
predicted for adverse transplant outcome.
Methods: Patients undergoing autologous stem cell transplants
from 1999 to 2003 at Rush University Medical Center were reviewed
to determine if having fewer lytic lesions prior to stem cell transplant
there would lead to longer disease free survival post-transplant. Pa-
tients with less than 3 lytic lesions were compared to those with more
than three lytic lesions regardless of subtype of myeloma or time to
transplant. 83 patients had autoSCT at RUMC during the time
frame, 12 patients did not have documented skeletal surveys and
one patient underwent alloSCT, so they were not included in the
analysis. Of the remaining 70, 44 patients had numerous lesions
while 26 had 0–2 lesions. The mean age at SCT for both groups
was 55.6 years. The various subtypes of myeloma for the group of
44 patients with numerous lesion is 25 with IgG, 6 with IgA, 1
with IgD, 5 with light chain, and 7 that were not specified, and for
the group of 26 patients with 0–2 lesions, 19 were IgG, 2 IgA, 4
not specified and 1 with POEMS. The average time to transplant
from diagnosis was 624 days with a range of 117–2294 for the group
with 0–2 lesions, and 511 days with a range of 93–7321 days for the
group with numerous lesions.
Results: 28/44 patients with numerous lesions had documented
disease progression with a median of 27 months from transplant,
with ranges of 4–74 months, while 19/26 patients with fewer lesions
progressed with median of 35 months and range of 12–75 months.
Prior to August 2008, 15/44 patients in the group with numerous le-
sions died, while 19/26 patients in the group with fewer lesions died.
Analysis with Kaplan Meyer survival curves showed no difference in
disease free survival and death between the two groups, with p-values
of 0.34 and 0.53 respectively. The estimated 5-year survival was 60%
versus 50% for pts with 0–2 lesions versus numerous lesions respec-
tively.
Conclusions:We conclude that extent of skeletal involvement de-
fined by number of lytic lesions does not predict for transplant out-
come in patients with multiple myeloma.GRAFT PROCESSING
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DEVELOPMENT OF A SEGMENT-BASED ALDEHYDE DEHYDROGENASE
ASSAY TO DETERMINE UMBILICAL CORD BLOOD UNIT (CBU) POTENCY
Shoulars, K.W.1, Gentry, T.2, Tracy, E.T.1, Page, K.1, Sun, J.1,
Winstead, L.2, Balber, A.E.2, Kurtzberg, J.1 1Duke University Medical
Center, Durham, NC; 2Aldagen, Durham, NC
Background: Banked, unrelated CBU provides access to trans-
plantation for patients lacking matched donors. However, after CB
transplantation (UCBT), up to 20% of patients experience primary
graft failure, suggesting that rapid assays to assess CB potency are
needed. Preliminary clinical studies demonstrated that post-thaw
colony forming units (CFU) predict neutrophil and platelet engraft-
ment as well as overall survival but, time (14 days) and variability
limit their usefulness as a potency assay. CFUs in fresh cord blood
are highly correlated with the number of cord blood cells expressing
aldehyde dehydrogenase (ALDHbr), an enzyme enriched in hemato-
poietic progenitor and stem cells. Therefore, we developed an assay
for ALDHbr cells in segments attached to CBUs to measure potency
for UCBT.
Methods: Fresh CBUs, donated to the Carolinas Cord Blood
Bank at Duke, were selected based on ALDHbr content (high1.0%,
medium0.4%, low0.1%) and divided into segments (100 ul) for
cryopreservation and post-thaw testing. Thawed segments werewashed to remove the DMSO with 5% dextran/albumin (DA) or
1% human serum albumin/phosphate buffered saline (HSA/PBS).
The segments were assayed for CFU [Methocult], ALDHbr [Alde-
fluor], viability, expression of CD34, CD45 and Glycophorin A
[flow cytometry] and total nucleated cell (TNC) count [Sysmex],
and total number of each cell population in the segment pre-cryo
and post-thaw was calculated.
Results:ALDHbr cells (85% CD34/45 positive) were reproduc-
ibly assayed by flow cytometry in fresh and frozen segments in less
than a day regardless of ALDHbr percentage. DA and HSA/PBS
washes reliably removed DMSO with little loss in the number of
CFU or ALDHbr cells, although TNC count was reduced. Ammo-
nium chloride lysis of red blood cells post-thaw reduced CFU and
ALDHbr cells, so an alternate procedure based on exclusion gating
of GLY A1 cells was adopted. Studies on segments derived from
the same cord showed that the number of ALDHbr cells could be re-
liably measured and that pre-cryo and post-thaw changes in CFU
and ALDHbr cells strongly correlated.
Conclusions: ALDHbr cell content of thawed CBU segments can
be measured rapidly and reliably by flow cytometry. Post-thaw
ALDHbr correlates with CFUs. Since post-thaw CFU values predict
engraftment, we propose further studies of a rapid, post-thaw assay
of ALDHbr content that could serve as a predictor of CBU potency
for neutrophil and platelet engraftment and overall survival after
UCBT.112
SIGNIFICANT EX-VIVO EXPANSION OF CORD BLOOD (CB) NATURAL
KILLER (NK) CELLS AND CONCOMITANT DECREASE IN CB T-CELLS BY
GENETICALLY REENGINEERED K562 CELLS (K562-MBIL15-41BBL)
Hochberg, J.1, Mar, B.1, Ayello, J.1, Day, N.1, van de Ven, C.1, Ricci, A.1,
Gurnani, L.1, Cairo, E.1, Campana, D.2, Cairo,M.S.1,3,4 1Morgan Stan-
ley Children’s Hospital NewYork Presbyterian, ColumbiaUniversity, New
York, NY; 2St. Jude Children’s Research Hospital, Memphis, TN; 3Mor-
gan Stanley Children’s Hospital New York Presbyterian, Columbia Uni-
versity, New York, NY; 4Morgan Stanley Children’s Hospital New York
Presbyterian, Columbia University, New York, NY
The limitations of the use of NK cells in adoptive tumor immuno-
therapy include lack of tumor recognition by NK cells and limited
numbers of functionally active NK cells (Shereck/Cairo et al, Pediatr
Blood Cancer, 2007). To circumvent these limitations, methods to
expand and activate peripheral blood NK cells have been developed
(Imai et al, Blood, 2005). We previously reported the successful ex-
pansion and functional activation of cord blood NK cells by ex-vivo
cellular engineering with a cocktail of antibody and cytokines
(Ayello/Cairo et al, BBMT, 2006). In this study we sought to develop
an improved CB NK cell expansion system for use in adoptive cellu-
lar immunotherapy strategies. Freshly isolated CB mononuclear
cells (CBMC) were cultured with modified K562 cells expressing
membrane bound IL15 and 4-1BB ligand (K562-mbIL15-41BBL;
Imai et al, Blood, 2005). After irradiation with 100Gy,
K562-mbIL15-41BBL cells were incubated in a 1:1 ratio with
CBMC1 10 IU/mL rhIL-2 for 7–14 days. CD3 and CD56 expres-
sion was determined by flow cytometry at Days 0, 7 and 14. On Day
0, CBMC included a population of CD561/CD3- NK cells of 3.9%
6 1.3%. After 7 days of culture with K562-mbIL15-41BBL cells the
percentage of NK cells increased to 71.7%6 3.9%, as compared to
9.7%6 2.4% in cultures with media alone and 42.6%6 5.9% in cul-
tures with wild-type K562 cells (p\0.01). Concomitantly, there was
a significant decrease in CB T-Cells vs culture with wild-type K562
or media alone (15.1 6 1.7% vs 35.7 6 2.4% vs 51 6 7.1%, respec-
tively) (p\0.001). Overall, this represented a 35-fold or 3374% 6
385% increase of the input NK cell number. This was significantly
increased compared to culture with wild-type K562 (1771% 6
300%, p\0.05). On Day 14, there remained a significant increase
in NK cell populations between CBMC incubated with modified
K562 cells compared to wild-type K562 cells and media alone
(62.0% 6 2.1% vs 27.9% 6 2.4% vs 5.5% 6 0.4%, p\0.001). A
standard cryopreserved UCB unit (25 mL) contains approximately
750  106 MNCs. By using the smaller 5mL aliquot (20%) of
a two-aliquot bag (150  106 MNCs x 3.9%5 5.8  106 NK cells),
this expansion method would hypothetically yield approximately 200
 106 CB NK cells after 7 days of culture. In summary, we have
Poster Session-I 45demonstrated CBMC can be ex-vivo expanded by K562 cells ex-
pressing membrane bound IL15 and 4-1BB ligand (K562-mbIL15-
41BBL) resulting in specific expansion of CB NK cells and decrease
in CB T-Cells.113
A ‘‘NO-WASH’’ ALBUMIN-DEXTRAN DILUTION STRATEGY FOR CORD
BLOOD (CB) THAW IS ASSOCIATED WITH A HIGH RATE OF ENGRAFT-
MENT AND A LOW INCIDENCE OF SERIOUS INFUSION REACTIONS
Rice, R.D., Abboud, M., Hawke, R.M., Schaible, A.M., Heller, G.,
Scaradavou, A., Barker, J.N. Memorial Sloan-Kettering Cancer Center,
New York, NY
The albumin-dextran dilution with centrifugation (‘‘wash’’) for CB
thaw used for children has been adopted for adults as a matter of con-
vention. An alternative CB dilution without centrifugation may be
advantageous for adults in whom any cell loss may be significant.
In contrast to a bedside thaw, it is still conducted in the controlled
laboratory environment. Therefore, we conducted a prospective
study of CB transplantation (CBT) using albumin-dextran dilution
with the hypothesis that the ‘‘no wash’’ thaw would be associated
with tolerable infusion reactions and a high rate of engraftment. Re-
cipients $20 kg were eligible. Patients [n 5 50; median 42 years
(range 7–66); median 72 kg (range 24–109)] were transplanted for
high-risk hematological malignancies with ablative (n 5 34) or
non-ablative (n 5 16) conditioning and double unit grafts to aug-
ment engraftment. 99 units were thawed with albumin-dextran dilu-
tion (1 RBC replete unit was washed). Units were 6/6 (n5 5), 5/6 (n
5 52) and 4/6 (n 5 42) HLA-A,B antigen, DRB1 allele matched to
the recipient. A 5:1 Gentran40/ 25% albumin solution was used.
RBC deplete units (n 5 96) were diluted $5.5 fold [median
200mls (range 200–500)]. The larger volume RBC replete units (n
5 3) were diluted $4 fold [median 400mls (range 400–535)] using
double tubing to connect to the transfer pack to prevent clogging.
All patients received pre-medication and pre- and post-hydration.
There were no serious adverse events related to infusion. 18 had
no reactions and 32 had reactions requiring additional therapy (2
transient hypoxia, 29 hypertension, 6 nausea, 3 pain, 1 rigor/fever).
Also, 1 had transient bradycardia and 6 had transient creatinine ele-
vation. Cumulative incidence (CI) of sustained donor engraftment
was 96% (95%CI:90–100) with neutrophil recovery at a median of
25 days (range 13–43) in ablative and 11 days (range 7–36) in non-
ablative recipients. CI of day 100 grade II-IV acute GVHD was
40% (95%CI:26–54), and 6 patients have chronic GVHD to date.
CI of day 180 transplant-related mortality is 24% (95%CI:11–37)
and 1 year overall survival is 63%(95%CI:49–78). In conclusion,
the dilution thaw technique is an alternative to wash in patients
$20 kg with cell dose yields and clinical outcomes that compare
favorably to a traditional wash. This technique is more efficient,
reduces unit manipulation, speeds time to infusion, reduces cell
loss, and may be the thaw technique of choice for adult CBT.
Post-Thaw Cell Dose Yields
Pre-thaw Post-thaw Post-thaw Post-thaw
TNC x
107/kgTNC x
107/kg% TNC
RecoveryCD341
ViabilityCD341 x
105/kg/unitCFU-GM x
104/kg/unitMedian 2.65 2.25 86% 90% 0.90 1.25
Range 1.06–6.87 0.92–5.36 50–121% 34–98% 0.13–3.69 0.00–4.38114
COLONY-FORMING-UNIT (CFU) ASSAY WITH HIGH-RESOLUTION
DIGITAL IMAGING: A RELIABLE SYSTEM FOR CORD BLOOD (CB) CFU
EVALUATION
Albano, M.S., Stevens, C.E., Dobrila, L.N., Scaradavou, A.,
Rubinstein, P. New York Blood Center, New York, NY
Among CB graft characteristics currently used as determinants of
quality and engraftment potential, only the CFU assay evaluates the
functional state and number of hematopoietic progenitor cells. Tra-
ditionally, classification and enumeration of CFU colonies are per-
formed manually by light microscopy, and the assay is timeconsuming, subjective and difficult to standardize. We developed
a strategy combining high resolution digital imaging and colony
staining with MTT, which allows testing of large numbers of CB
samples in a ‘‘high throughput’’ approach. CFU growth was assessed
in 2159 CB units; samples were obtained after processing (AXP
system). Our new approach permits a more precise analysis, classifi-
cation, and enumeration of the different colonies, and standardiza-
tion of the assay. Furthermore, stored CFU images can be
reviewed prior to the release of a CBU for transplantation. The num-
ber of CFUs (179 6108/uL) correlated strongly with Total Nucle-
ated Cell count (R2: 0.33), Mononuclear Cell count (MNC
1nucleated RBC, R2: 0.35), and especially with pre-processing
CD341 cell content (R2: 0.8, all p\0.001). Comparison with results
obtained by the traditional CFU assay when testing was performed
on pre-processing samples showed minimal difference (10–15%) in
the CFU/uL or CFU/MNC ratio. CFU evaluation from a frozen-
thawed segment attached to the CBU bag is now underway. Even
though a small number of segments were tested so far (n 5 15),
CFU/uL correlated with the CBU’s respective pre-freeze CD341
cells (R2: 0.78), and with the post-thaw CD341 cells from the
same segment (R2: 0.74). CD341 cell viability was.93% in all seg-
ments. In summary, CFUs can be enumerated reliably from CB sam-
ples with a new strategy that can be standardized. The feasibility of
CFU growth from thawed segments was also evaluated, and CFU
yield correlated strongly with post-processing and segment-derived
CD341 cell counts. This assay can be used as a practical quality con-
trol measure of the cryopreservation process prior to a CBU release
for transplantation. Studies are in progress to assess whether CFU
yield from a segment could predict engraftment and, therefore,
used for the selection of CB units for transplantation.115
REGULATORY T CELL S (Tregs) CAN BE ISOLATED FROM G-CSF MOBI-
LIZED PBSC AFTER MONOCYTE DEPLETION AND INHIBIT ANTI-STEM
CELL T CELL ALLOREACTIVITY
Mahmud, D., Rondelli, D. University of Illinois at Chicago, Chicago, IL
Small numbers of human CD41CD251FoxP31 Tregs can be
isolated from normal peripheral blood, thus their potential clinical ap-
plication is limited. In this study we tested whether Granulocyte Col-
ony-Stimulating Factor (G-CSF)-mobilized peripheral blood stem
cells (PBSC) from healthy donors can represent a useful source of
CD41CD251 cells with regulatory activity. We utilized antibodies
conjugated to microbeads (Miltenyi Biotec Inc, Auburn, CA) to immu-
nomagnetically separate the cells on a MidiMACS device (Miltenyi)
and checked the purity after isolation by flow cytometry. Starting
from on average 4.0 6 1.8  108 unseparated PBSC (n 5 3) we
positively selected 2.46 0.8  106 CD341 cells (.90% purity). We
then utilized the CD34- cell fraction to isolate Tregs. Due to the large
content of CD4dim monocytes in the initial cell product, we initially
depleted the PBSC of CD141 cells and then utilized a two-step pro-
cess that includes a CD41 cell negative selection (using a cocktail of
biotin-conjugated antibodies against CD8, CD14, CD19, CD16,
CD36, CD56, CD123, TCR g/d and Glycophorin-A) followed by
a positive selection of CD251 cells (Treg isolation kit, Miltenyi).
This process allowed us to obtain 1.26 1  106 CD41CD251 cells
with a purity of.70%. Intracellular expression of FoxP3 was also de-
tected in purified CD41CD251 cells by flow cytometry. Primary
mixed leukocyte cultures (MLC) were performed with irradiated
CD341 cells isolated from PBSC and HLA mismatched blood
CD31 responders for 6 days and T cell response was measured by
a 3H-thymidine uptake assay. Tregs isolated from PBSC were added
to the MLC at 1:2 Treg:responder ratio to test their regulatory func-
tion. Control experiments were performed using CD41CD25- cells.
Addition of Tregs isolated from PBSC resulted in 766 17% inhibition
of anti-CD34 T cell alloreactivity (cpm: 190006 530 vs 45906 1880)
(n5 3), while control CD41CD25 neg cells did not show suppressive
activity. These findings show that after isolation of CD341 cells, ade-
quate numbers of Tregs can be obtained from the CD34- cell fraction
of PBSC by using a three-step process. In addition, since Tregs isolated
from PBSC suppressed in-vitro T cell alloreactivity against CD341
cells, these findings will prompt the design of pre-clinical studies to
test the combination of PBSC-derived CD341 cells and Tregs in
HLA mismatched transplantation.
